Upstream Bio announced its participation in two prominent investor conferences scheduled for March 2026, providing the company with opportunities to discuss its clinical development strategy with institutional investors and healthcare sector analysts. CEO Rand Sutherland will represent the company at the TD Cowen 46th Annual Health Care Conference on March 4, followed by an appearance at the Leerink Partners Global Healthcare Conference on March 9.
The company is advancing verekitug, a TSLP receptor antagonist currently in Phase 2 clinical trials for multiple severe respiratory indications. The asset is being evaluated across a therapeutic spectrum that includes chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease, each representing significant market opportunities within respiratory medicine.
These conference presentations represent a standard component of Upstream Bio's investor relations calendar, offering the company a platform to update the financial and clinical communities on development progress and pipeline momentum during a critical period of clinical advancement.